Picture of CVS Health logo

CVS — CVS Health News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

CVS Health Q2 revenue beats estimates, outlook raised

CVS Health Q2 revenue beats estimates, outlook raised


Overview

  • U.S. health solutions provider's Q2 revenue rose 7.3% yr/yr, beating analyst expectations

  • Adjusted EPS for Q2 beat consensus, driven by improved Health Care Benefits segment margin recovery

  • Company raised full-year 2026 guidance for EPS and cash flow from operations


Outlook

  • CVS raises 2026 GAAP diluted EPS guidance to $6.84-$7.04 from $6.24-$6.44

  • Company lifts 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50

  • CVS increases 2026 cash flow from operations guidance to at least $11.5 bln from at least $9.5 bln


Result Drivers

  • HEALTH CARE BENEFITS MARGIN RECOVERY - Adjusted operating income rose sharply in the Health Care Benefits segment, driven by improved performance in the Government business and the absence of a prior-year premium deficiency reserve

  • PHARMACY DRUG MIX AND BRAND INFLATION - Health Services segment revenue grew due to pharmacy drug mix and brand inflation, partially offset by pharmacy client price improvements

  • RITE AID ASSET ACQUISITIONS - Increased prescription volume in Pharmacy & Consumer Wellness segment was supported by contributions from Rite Aid asset acquisitions and brand inflation, though offset by regulatory-related price reductions and reimbursement pressure


Company press release: ID:nPnbvjs38a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$106.10 bln

$100.11 bln (19 Analysts)

Q2 Adjusted EPS

Beat

$2.58

$1.85 (23 Analysts)

Q2 EPS

$2.31


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for CVS Health Corporation is $113.00, about 8.2% above its August 4 closing price of $104.42

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Aug 5 - CVS raises annual profit forecast on improved drug revenues

  • Aug 4 - Weis Markets Q2 profit falls as pharmacy pricing headwinds weigh

  • Aug 4 - Dialysis provider DaVita's Q2 results beat estimates, aided by higher average rates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on CVS Health

See all news